Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
4,159
Total Claims
$3.2M
Drug Cost
611
Beneficiaries
$5,248
Cost/Patient
Risk Score Breakdown 17/100
Score components are additive. Read full methodology
Peer Comparison vs. 13,194 Neurology providers
-14%
Opioid rate vs peers
1.1% vs 1.3% avg
+30%
Cost per patient vs peers
$5,248 vs $4,034 avg
+47%
Brand preference vs peers
13.9% vs 9.4% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
1.1%
Opioid Rate
47
Opioid Claims
$1,217
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 571 claims · $2.5M
Generic: 3,549 claims · $679K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Diroximel Fumarate | 32 | $317K |
| Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | $302K |
| Teriflunomide | 30 | $284K |
| Fingolimod Hcl | 30 | $214K |
| Ofatumumab | 12 | $166K |
| Immune Globul G/Gly/Iga Avg 46 | 27 | $148K |
| Interferon Beta-1a | 18 | $140K |
| Dimethyl Fumarate | 33 | $113K |
| Glatiramer Acetate | 18 | $103K |
| Interferon Beta-1b | 11 | $95K |
| Glatiramer Acetate | 16 | $64K |
| Dalfampridine | 24 | $55K |
| Erenumab-Aooe | 40 | $50K |
| Rimegepant Sulfate | 36 | $50K |
| Dalfampridine | 12 | $46K |
Prescribing Profile
70
Unique Drugs
17.0
Anomaly Score
Patient Profile
68
Avg Age
57%
Female
1.35
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About